Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
M.D. Anderson Cancer Center
University of Pittsburgh
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Big Ten Cancer Research Consortium
IO Biotech
Merck Sharp & Dohme LLC
Seagen Inc.
H. Lee Moffitt Cancer Center and Research Institute
Arcus Biosciences, Inc.
AstraZeneca
University of Pittsburgh
Wake Forest University Health Sciences
Duke University
Seagen Inc.
iLeukon Therapeutics, Inc.
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
Emory University
Gilead Sciences
Hoffmann-La Roche
UNICANCER
Klus Pharma Inc.
Dana-Farber Cancer Institute
ImmunityBio, Inc.
GlaxoSmithKline
HUYABIO International, LLC.
University of Washington
Merck Sharp & Dohme LLC
NRG Oncology
Sotio Biotech Inc.
NovoCure Ltd.
University of Southern California
ImmuneSensor Therapeutics Inc.
The Christ Hospital
Sanofi
Latin American Cooperative Oncology Group
BerGenBio ASA
University of Alabama at Birmingham
Incyte Corporation
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
Celgene
GlaxoSmithKline
Yale University
Grid Therapeutics
NYU Langone Health
Peking University
University of Miami